GSK’s blood cancer test drug halves risk of disease progression: Data
British drugmaker, GSK Plc.’s multiple myeloma drug, Blenrep, reduced the risk of disease progression or death by about 50% when compared to a
Drugs
Health
Pharma
Drugs
Health
Pharma
AstraZeneca, Daiichi’s breast cancer drug trials show rise in survival
HQ Team June 3, 2024: An antibody-drug conjugate, jointly being developed by AstraZeneca and Daiichi Sankyo, has been shown in end-stage clinical trials
Drugs
Health
Pharma
Global pandemic accord may see the light of day in 2025, ‘or earlier’: WHO
Negotiations at reaching a global accord to help fight pandemics better will conclude by 2025 or “earlier if possible at a special session
Drugs
Health
Pharma
Pfizer’s drug helps people with rare lung cancer live longer, data shows
Sixty percent of the patients treated with Pfizer’s Lorbrena drug, for a rare form of advanced lung cancer, were alive without disease progression
Drugs
Health
Pharma
Hunger, famine, stare at displaced Sudanese, WHO appeals for funds
Eighteen million people are “acutely” hungry in conflict-ridden Sudan as a famine is on the horizon and 800,000 civilians get ready for large-scale
Health
Medical
Pharma
Medical education in the UK inflicting ‘pervasive harm’ on students: Expert
Technology-based medical training has led to junior doctors avoiding the ward to stick to the electronic tablet — a healthcare crisis that will
Drugs
Health
Pharma
Biogen’s ALS drug gets European Commission’s marketing nod
The European Commission has granted marketing approval for Biogen Inc.’s therapy for the treatment of a form of amyotrophic lateral sclerosis.
Drugs
Health
Pharma
US reports a third human case of highly pathogenic avian influenza
A dairy farm worker in Michigan, US, has been infected with highly pathogenic avian influenza from sick cows —the third such case in America
Drugs
Health
Pharma
J & J to buy rights for experimental skin disorder drug for $1.25 billion
Johnson & Johnson has agreed to buy the rights for an investigational skin disorder treatment from Numab Therapeutics for $1.25 billion.
Drugs
Health
Pharma
US drug regulator clears Amgen’s biosimilar to treat rare blood disorder
The US drug regulator has approved Amen’s biosimilar, Bkemv, to treat rare blood disorders, according to a statement from the Food and Drug